Cardiodan® 1.25

Each 200 mg flavored tablet contains:

Pimobendan 1.25 mg; Excipients q.s.ad. 1 tablet

-Treatment of canine congestive heart failure (CHF) caused by dilated cardiomyopathy or valve regurgitation (mitral and/or tricuspid valve regurgitation).

-Treatment of dilated cardiomyopathy (CMD) in large breed dogs. When used in cases of CMD in large breed dogs, the time to onset of CHF or sudden death is significantly prolonged

and results in prolongation of the life span of the animal.

-Treatment of CMD in the preclinical stage (asymptomatic with increased end-systolic and end-diastolic diameters of the left ventricle), mainly in Doberman Pinschers after

echocardiographic diagnosis of heart disease.

-Treatment of dogs with myxomatous mitral valve disease (MVD) in the preclinical phase (asymptomatic with systolic mitral murmur and evidence of an enlarged heart) to delay the

onset of clinical symptoms of heart failure.